Noninvasive tumor genotyping for cancer detection

Non-small cell lung cancer is one of the leading causes of cancer-related deaths, mainly because relapses are often detected too late. This research project aims to validate an innovative method to monitor patients after treatment by detecting tiny traces of tumor DNA circulating in the blood. Using a highly sensitive genome sequencing approach, it will be possible to identify a recurrence of the disease much earlier than with current imaging techniques. For the Institut du cancer de Montréal and its partners, the expected benefits are significant: providing doctors with a reliable tool to adjust treatments more quickly, reducing the need for costly follow-up exams, and improving both quality of life and survival for patients. For the public, this means access to more effective care, less stress and uncertainty during medical follow-ups, and a more efficient use of healthcare resources. Finally, this project will strengthen Canadas leadership in precision oncology and deliver concrete benefits to society as a whole.

Faculty Supervisor:

Alexandre Cheng

Student:

Partner:

Institut du cancer de Montréal

Discipline:

Engineering

Sector:

Other services (except public administration); Professional, scientific and technical services

University:

École de technologie supérieure

Program: